NEW YORK (GenomeWeb) – After posting a 6 percent gain in January, the GenomeWeb Index rose nearly 5 percent in February, on par with the Dow Jones Industrial Average, and outperforming a 4 percent gain from the Nasdaq. The Index underperformed the Nasdaq Biotechnology Index, however, which gained 7 percent in February.

Stock performance in the February GenomeWeb Index was almost entirely positive, with 22 of the 26 stocks seeing gains and only four seeing losses. Many of the gains and losses in February were less dramatic than the ones last month, however.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.